Medindia

X

Rosetta Genomics Announces Transfer of MicroRNA-based Liver Therapeutics Project With Isis Pharmaceuticals, Inc. to Regulus Therapeutics LLC

Tuesday, September 23, 2008 General News J E 4
Advertisement
REHOVOT, Israel and JERSEY CITY, New Jersey, September 23 Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader inthe development of microRNA-based diagnostics and therapeutics, announcedtoday the transfer of its microRNA-based liver cancer therapeutics projectwith Isis Pharmaceuticals (Nasdaq: ISIS) to Regulus Therapeutics, a jointventure between Alnylam Pharmaceuticals and Isis Pharmaceuticals focused onthe development of microRNA-based therapeutics. Regulus and Rosetta Genomicswill continue collaborating under the same terms and conditions.

The project, partially funded by the Israel-U.S. Binational IndustrialResearch and Development (BIRD) foundation, is focused on the development ofmicroRNA-based therapeutics for hepatocellular carcinoma, the most commonform of liver cancer.

About MicroRNA

MicroRNAs (miRNAs) are recently discovered, naturally occurring, smallRNAs that act as master regulators and have the potential to form the basisfor a new class of diagnostics and therapeutics. Since many diseases arecaused by the abnormal activity of proteins, the ability to selectivelyregulate protein activity through microRNAs could provide the means to treata wide range of human diseases. In addition, microRNAs have been shown tohave different expression in various pathological conditions. As a result,these differences may provide for a novel diagnostic strategy for manydiseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.Founded in 2000, the company's integrative research platform combiningbioinformatics and state-of-the-art laboratory processes has led to thediscovery of hundreds of biologically validated novel human microRNAs.Building on its strong IP position and proprietary platform technologies,Rosetta Genomics is working on the application of these technologies in thedevelopment of a full range of microRNA-based diagnostic and therapeutictools, focusing primarily on cancer and various women's health indications.The company expects that the first microRNA diagnostic tests applying itstechnology will be launched by licensed clinical laboratories in the UnitedStates in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's futureexpectations, plans and prospects, including without limitation, statementsrelating to the role of microRNAs in human physiology and disease, thepotential of microRNAs in the diagnosis and treatment of disease and theexpected timing of submission for approval and launch of diagnostic testsusing our microRNA technology constitute forward-looking statements for thepurposes of the safe harbor provisions under The Private SecuritiesLitigation Reform Act of 1995. Actual results may differ materially fromthose indicated by these forward-looking statements as a result of variousimportant factors, including risks related to: Rosetta's approach to discovermicroRNA technology and to work on the application of this technology in thedevelopment of novel diagnostics and therapeutic tools, which is unproven andmay never lead to marketable products or services; Rosetta's ability to fundand the results of further pre-clinical and clinical trials; Rosetta'sability to obtain, maintain and protect the intellectual property utilized byRosetta's products; Rosetta's ability to enforce its patents againstinfringers and to defend its patent portfolio against challenges from thirdparties; Rosetta's ability to obtain additional funding to support itsbusiness activities; Rosetta's dependence on third parties for development,manufacture, marketing, sales, and distribution of products; Rosetta'sability to successfully develop its candidate tools, products and services,all of which are in early stages of development; Rosetta's ability to obtainregulatory clearances or approvals that may be required for its products andservices; the
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Pinon Management Partners With Silverchair Learnin...
S
WBFF 'Face Of Muscle Pharm' Winners